Skip to main content

Table 5 Adverse events

From: A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)

 

Grade1

Grade2

Grade3

Grade4

All grade

Grade ≥ 3

Total

38 (83%)

18 (39%)

7 (15%)

–

41 (89%)

7 (15%)

Hematologic

 Neutropenia

5

4

1

–

10 (22%)

1 (2%)

 Leukocytopenia

7

6

–

–

13 (28%)

–

 Anemia

13

5

2

–

20 (43%)

2 (4%)

 Thrombocytopenia

6

2

–

–

8 (17%)

–

Gastrointestinal

 Nausea

9

2

1

–

13 (26%)

1 (2%)

 Vomiting

2

0

1

–

3 (7%)

1 (2%)

 Anorexia

5

4

2

–

11 (24%)

2 (4%)

 Diarrhea

4

5

2

–

11 (24%)

2 (4%)

 Abdominal pain

–

–

1

–

1 (2%)

1 (2%)

Others

 Total bilirubin elevation

4

–

–

–

4 (9%)

–

 AST elevation

2

–

–

–

2 (4%)

–

 ALT elevation

1

–

–

–

1 (2%)

–

 Creatinine elevation

1

1

–

–

2 (4%)

–

 Aphthous stomatitis

3

2

–

–

5 (11%)

–

 Fatigue

11

7

–

–

18 (39%)

–

 Pigmentation

11

–

–

–

11 (24%)

–

 Rash

3

3

–

–

6 (13%)

–

 Chest pain

–

1

–

–

1 (2%)

–

  1. Abbreviations: AST aspartate aminotransferase, ALT alanine aminotransferase